论文部分内容阅读
目的对妇科盆腔肿块患者进行血清人附睾分泌蛋白4(HE4)与癌胚抗原125(CA125)联合检测,以探讨其临床诊断价值。方法选取2014年6月-2015年6月在该院妇科诊断为盆腔肿块拟行手术的患者110例作为研究对象,其中卵巢癌患者38例(卵巢癌组),盆腔良性肿块患者72例(良性肿块组);另选取同期在该院进行健康体检的妇女50例作为对照组。分别采用酶联免疫吸附法与电化学发光法对3组患者的血清HE4与CA125含量进行测定并比较。结果与对照组比较,卵巢癌组与良性肿块组患者血清HE4及CA125水平均明显升高,差异具有统计学意义(P<0.05);与良性肿块组比较,卵巢癌组患者血清HE4及CA125水平均明显升高,差异均有统计学意义(P<0.05);HE4、CA125两项联合检测的敏感度为94.7%,与HE4单项检测、CA125单项检测的敏感度相比明显提高,差异具有统计学意义(P<0.05),而特异度及诊断符合率与单项检测比较,差异无统计学意义(P>0.05)。结论血清HE4及CA125是两种较为理想的盆腔肿块标志物,两者的水平测定对鉴别诊断妇科盆腔肿块良恶性疾病具有一定的作用,并且两者联合检测的敏感性明显高于单项检测,有助于提高盆腔肿块患者良恶性疾病的诊断价值。
Objective To evaluate the clinical value of serum human epididymis secretory protein 4 (HE4) and carcinoembryonic antigen 125 (CA125) in gynecologic pelvic masses. Methods A total of 110 patients with pelvic masses undergoing gynecological examinations in our hospital from June 2014 to June 2015 were selected as the study subjects, including 38 patients with ovarian cancer (ovarian cancer group) and 72 patients with benign pelvic masses (benign Lumps group). Another 50 women who took physical examination during the same period in the hospital were selected as the control group. Enzyme-linked immunosorbent assay and electrochemiluminescence were used to detect and compare the serum levels of HE4 and CA125 in three groups. Results Compared with the control group, the levels of serum HE4 and CA125 in ovarian cancer group and benign tumor group were significantly increased, the difference was statistically significant (P <0.05); Compared with benign tumor group, the serum levels of HE4 and CA125 (P <0.05). The combined sensitivity of HE4 and CA125 was 94.7%, which was significantly higher than that of HE4 single test and CA125 single test, the difference was statistically significant (P <0.05), while the specificity and diagnostic coincidence rate compared with single test, the difference was not statistically significant (P> 0.05). Conclusions Serum HE4 and CA125 are two ideal markers of pelvic masses. The determination of serum levels of both of them may play a certain role in the differential diagnosis of benign and malignant diseases of pelvic masses. The sensitivity of the combined detection is significantly higher than that of single detection Help to improve the diagnosis of benign and malignant diseases in pelvic masses.